Table 2.

Summary of patients’ characteristics and omalizumab protocol.

	Patient 1	Patient 2	Patient 3
Age (years)	60	60	76
Histology	HGSOC	Clear cell	HGSOC
Surgical debulking	Yes	Yes	Yes
BRCA status	Mutated	Wild-type	Wild-type
Atopy	No	no	Yes (Latex)
Treatment administered	Carboplatin	Carboplatin	Carboplatin
N° of drug administrations before HRs (total)	7	13	15
Clinical manifestations of initial HRs	Urticaria, dyspnea, hypotension, O2 desaturation	Flushing, malaise, vomiting, nausea	Flushing, chest discomfort, sweating
HRs Grade	3	2	2
Skin test	Positive (IDT 0.01 mg/ml)	Positive (IDT 0.1 mg/ml)	Negative
Details of breakthrough reactions	2nd DD, 9th step Urticaria, itching, flushing, throat constriction	2nd DD, 14th step Thoracic pain, nausea, vomiting, flushing, face angioedema	2nd DD, 8th step Urticaria, angioedema, flushing, throat constriction
Total serum IgE (UI/L)	925	NA	39.9
Dose of omalizumab	600 mg	600 mg	600 mg
Timing of omalizumab administration	−15 days and − 2 days Prior to the first optimized DD cycle, and then −2 days prior to each subsequent DD	15 days and − 2 days Prior to the first optimized DD cycle, and then −2 days prior to each subsequent DD	15 days and − 2 days Prior to the first optimized DD cycle, and then −2 days prior to each subsequent DD
N* of DD cycles successfully concluded	4	4	4
Adverse events to omalizumab	No	No	No

DD: drug desensitization; BRCA: breast related cancer antigen; IDT: intradermal test; FIGO: Federetion of Gynecology and Obstetrics; HGSOC: high grade serous ovarian cancer; HRs: Hypersensitivity reactions; NA: not available.